New antiretroviral drugs

被引：7

作者：

Hanson K. ^{[1
]}

Hicks C. ^{[1
]}

机构：

[1] Duke University Medical Center, Division of Infectious Diseases and International Health, Box 3879, Durham

来源：

Current HIV/AIDS Reports | 2006年 / 3卷 / 2期

关键词：

Maraviroc; Enfuvirtide; Integrase Inhibitor; CCR5 Antagonist; Fusion Inhibitor;

D O I：

10.1007/s11904-006-0024-z

中图分类号：

学科分类号：

摘要：

Despite the availability of 21 antiretroviral drugs approved for the treatment of HIV infection, current combination regimens remain hampered by issues of toxicity, convenience, cost, incomplete viral suppression, and drug resistance. Expansion of the currently available therapeutic options through the reformulation of available agents, discovery of new compounds with antiretroviral activity, and the exploitation of novel drug targets are critical. This review describes the status of new nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, and fusion inhibitors. We also summarize new classes of antiretroviral therapy in clinical development including the attachment inhibitors, chemokine receptor antagonists, integrase inhibitors, and maturation inhibitors. Copyright © 2006 by Current Science Inc.

引用

页码：93 / 101

页数：8

共 59 条

[1]

Mahungu T., Ballinger J., Swaden L., Et al., Switching to Saquinavir 500/r-based regimens in subjects on HAART is not associated with loss of virologic control, 10th European AIDS Conference, (2005)

[2]

Awni W., Chiu Y.-L., Zhu T., Et al., Significantly reduced food effect and pharmacokinetic variability with a novel lopinavir/ritonavir tablet formulation, 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment, (2005)

[3]

Geleziunas R., Gallagher K., Zhang H., Et al., HIV-1 resistance profile of the novel nucleoside reverse transcriptase inhibitor beta-D-2′,3′-dideoxy-2′,3′-didehydro-5- fluorocytidine (Reverset), Antivir Chem Chemo, 14, pp. 49-59, (2003)

[4]

Hammond J.L., Parikh U.M., Koontz D.L., Et al., In vitro selection and analysis of human immunodeficiency virus type 1 resistant to derivatives of beta-2′,3′-didehydro-2′,3′- dideoxy-5-fluorocytidine, Antimicrob Agents Chemother, 49, pp. 3930-3932, (2005)

[5]

Murphy R.L., Schurmann J.D., Kravec I., Et al., Pharmacokinetics, safety and antiviral activity of the nucleoside Reverset following single doses in HIV-1 infected patients, 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, (2003)

[6]

Murphy R.L., Schurmann D., Beard A., Et al., Potent anti-HIV-1 activity of Reverset™ following 10 days of monotherapy in treatment-naive individuals, 15th International AIDS Conference, (2004)

[7]

Cohen C., Katlama C., Murphy R., Et al., Antiretroviral activity and tolerability of Reverset (D-d4FC), a new fluorocytidine nucleoside analog, when used in combination therapy in treatment-experienced patients: Results of phase IIb study RVT-203, 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment, (2005)

[8]

Bethell R., Collins P., Holdich T., Et al., In vitro and in vivo antiviral activity of SPD754 against wild-type and NRTI-resistant viruses, 15th International AIDS Conference, (2004)

[9]

Holdich T., Dennis K., Influence of food upon the pharmacokinetics of SPD754, 9th European AIDS Conference, (2003)

[10]

Bethell R., Adams J., De Muys J., Et al., Pharmacological evaluations of a dual deoxycytosine analogue combination: 3TC and SPD754, 11th Conference on Retroviruses and Opportunistic Infection, (2004)

← 1 2 3 4 5 6 →